Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery Chemoembolization After First-line Chemotherapy and Immunotherapy

Inclusion Criteria:

1. Squamous cell carcinoma of the lung confirmed by histology or cytology;
2. According to the TNM staging system of the 9th edition of American Cancer Association, it was assessed as stage IV.
3. Has received standard first-line chemotherapy immunotherapy for 4~6 cycles, and achieved partial remission or disease stability according to the efficacy evaluation of RECIST1.1;
4. The patient is 18-80 years old;
5. ECOG PS score is 0-1;
6. The main organ functions meet the following criteria: (1) Blood routine examination: hemoglobin (HB) ≥ 90g/L; Leukocyte (ANC) ≥ 3.0× 109/L; Neutrophils ≥ 1.5× 109/L; Platelet (PLT) ≥ 75× 109/L; (2) Biochemical examination: albumin (ALB)≥29g/L; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2uln; Total bilirubin (TBIL) ≤ 1.5 ULN; Creatinine ≤ 1.5 ULN;
7. Patients and/or their families agree to participate in clinical trials and sign informed consent forms;
8. No history of other malignant tumors;
9. No active infection;
10. Be able to cooperate with research follow-up;
11. At least one measurable lesion (according to RECIST 1.1);
12. The expected survival time is more than 3 months.

Exclusion Criteria:

1. There is epidermal growth factor receptor (EGFR) sensitive mutation or anaplasticlymphomakinase (ALK) gene translocation;
2. Have a history of allergy to contrast agents or chemotherapy drugs;
3. Received other anti-tumor treatments other than standard first-line chemotherapy immunotherapy;
4. Arrhythmia with myocardial ischemia or myocardial infarction above grade II and poor control (including QTc interval ≥450ms for men and ≥ 470 ms for women);
5. Coagulation function is seriously abnormal and cannot be corrected;
6. Hypertension patients still have poor blood pressure control (systolic blood pressure > >160mmHg, diastolic blood pressure > 100 mmhg) after antihypertensive drugs treatment;
7. Pregnant or lactating female patients;
8. Have a history of mental illness or psychotropic drug abuse;
9. Patients with symptomatic brain metastasis;
10. Patients with autoimmune diseases;